News & Press Release

FDA OKS CHANGES FOR INSIGHTEC’S EXABLATE

28
January

MR-guided focused ultrasound (MRgFUS) developer INSIGHTEC has received U.S. Food and Drug Administration (FDA) clearance for a new version of its Exablate device and a change in labelling.

The new version of system is cleared for the treatment of symptomatic uterine fibroids, and with the updated labelling, fibroid tissue ablation can now be considered for patients who wish to retain fertility, the company said. Link to full article.

More Articles

Press Release
Press Release

FDA OKS CHANGES FOR INSIGHTEC’S EXABLATE

Press Release
Press Release

INSIGHTEC’S EXABLATE SYSTEM SPARES THE UTERUS WHEN TREATING UTERINE FIBROIDS

Font Resize